Table 1.
Patient demographic and clinical characteristics
MT, mutant; WT, wild type; ECOG, Eastern Cooperative Oncology Group; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine plus oxaliplain; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; VEGF, vascular endothelial growth factor.